ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $15,234.96 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,028 shares of the stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $15,234.96. Following the transaction, the insider now owns 22,257 shares in the company, valued at approximately $329,848.74. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Kihara also recently made the following trade(s):

• On Wednesday, March 26th, James Kihara sold 1,095 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.05, for a total transaction of $18,669.75.
• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Trading Up 6.1 %

NASDAQ:ACAD opened at $14.96 on Thursday. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 19.18 and a beta of 0.54. The firm has a fifty day simple moving average of $17.74 and a two-hundred day simple moving average of $16.98. ACADIA Pharmaceuticals Inc. has a 12 month low of $13.40 and a 12 month high of $20.68.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Virtus Fund Advisers LLC acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter worth $39,000. R Squared Ltd acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter worth $47,000. GF Fund Management CO. LTD. acquired a new stake in ACADIA Pharmaceuticals in the fourth quarter worth $64,000. KBC Group NV grew its holdings in ACADIA Pharmaceuticals by 67.0% in the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 2,044 shares during the period. Finally, Globeflex Capital L P bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at $168,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ACAD has been the subject of several research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “hold” rating and a $22.00 price objective for the company. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Finally, Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $23.93.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.